Discover the latest hgh research at the Human Growth Hormone Guide

Excerpted ,Westport, apr 26 (Reuters Health)

Treatment with human growth hormone affects several markers of bone formation, bone density and collagen turnover in healthy adults, according to new findings published in April 1999 issue of The Journal of Clinical Endocrinology and Metabolism.

The investigation examined the effects of HGH therapy on biochemical markers of bone and collagen turnover in 99 healthy volunteers. The subjects were randomized to either placebo or HGH, at 0.1 IU/kg per day, for 28 days, which was followed by a 56 day washout period.

Levels of all of the biochemical markers studied were increased relative to baseline and placebo in HGH-treated patients at 21 days. Many of these "HGH induced changes in the bone and collagen markers persist long after HGH withdrawal", the researchers found in particular, significant increases in procollagen type III and osteocalcin were still detected on the last day of the study. Another important study finding is that men are more sensitive than women to the effects of HGH on bone and collagen turnover.

The substantial increase of bone density remodeling achieved with human growth hormone may be helpful during late menopause with decreased bone turnover and impaired osteoblastic function. Using growth hormone to prevent physiological bone density loss that occurs with age seems possible, but has to be discussed on an ethical and economic basis.

Excerpted from Journal of HGH, Issue: Jan 15,2001. Wuster C, Harle U, Muller C, Knauf K, Koppler D, schwabe C, Ziegler R. Department of Internal Medicine I-Endocrinology and Metabolism, University Medical Clinic Heidelberg, Germany. Article provided by the National Library of Medicine.

22nd Annual Meeting of the American Society for Bone and Mineral Research
Day 1 - September 22, 2000
Treatment for Osteoporosis: New Drugs and New Data on Old Drugs
Hgh Research by Ego Seeman, MD

There is some hgh research evidence showing that compounds such as human growth hormone or insulin-like growth factor I (IGF-I) can increase periosteal apposition, enlarging bone and increasing its bending strength. For example, Ammann and colleagues[34] reported that IGF-1 increased periosteal apposition, whereas pamidronate reduced endocortical resorption. In addition, IGF-I increased the external diameter of the midshaft tibia and femoral neck.
Hermann and coworkers[35] studied the effects of IGF-I and M-CSF on growing mouse bone. Fifty 7-week-old male C57BL/6J mice were assigned to placebo, IGF-I, M-CSF, or both. M-CSF and the combination of IGF-I + M-CSF increased bone strength. Elastic strength increased by 14% (nonsignificant) with IGF, 31% with M-CSF, and 35% with the combination. Maximum strength increased by 9% (nonsignificant) with IGF, 23% with M-CSF, and 22% with the combination. Whole bone absolute masses were not altered, but mineralization of the epiphysis increased by 4.4% with M-CSF and by 4.9% with the combination. All treatments increased diaphyseal mineralization compared with placebo: 1.8% with IGF, 2.3% with M-CSF, and 2.9% with the combination. None of the treatments increased bone formation rate. Combined treatment increased periosteal active mineralizing perimeter compared with placebo (71%); the relative increase with M-CSF alone was 47%. M-CSF and the combination also had a greater effect on femoral mechanical and compositional properties than did IGF-I alone. The results suggest that M-CSF can act as an anabolic agent, possibly indirectly through coupled activation of osteoblasts through osteoclasts. The hgh research showed that combined use of IGF-I and M-CSF may be more potent. More hgh research taking such a specific structural and biomechanical approach to the design and evaluation of drug therapies is needed.